(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Garmezy discussing a phase 1 trial of mevrometostat (PF-06821497), a potent and ...

ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Pornlada Likasitwatanakul discussing the effect of HLA class I expression on the tumor immune ...

ASCO 2025 post-hoc analysis of TheraP, clonal hematopoiesis, metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA-617, cabazitaxel, PSMA-targeted radioligand.

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer rapid oral abstract session and a presentation by Dr. Rikke Eefsen discussing the CA209-8TY trial, a randomized phase 2 trial of ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Session State of the Art Lecture: Personalizing treatment for patients with ...

The initial insertion of a suprapubic catheter (SPC), a procedure referred to as a suprapubic cystostomy, can be performed under local or general anesthesia with a trocar system, using cystoscopic or ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Scott T. Tagawa discussing ProstACT Global, a phase 3 study of 177 ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Amir Iravani discussing the landscape of approved PSMA imaging agents. Over the last several ...